PECAM1 and neoplasm: By measuring tumor volume (Figure S7A-B), recording the survival time of the tumor-bearing mice (Figure S7C), and assessing VM formation through PAS-CD31 staining (Figure S7D-E), we explored the contribution of exosomal circCMTM3-involved VM formation to resistance against anti-angiogenic therapy.